CD8A and cancer: The introduction of monoclonal antibodies that target immune-inhibitory receptors, known as checkpoint inhibitors, has been an immense breakthrough in immuno-oncology, and has greatly improved the clinical outcomes of several cancers.36 This therapeutic strategy can enhance the efficacy of antitumour-immune responses, as well as revitalising exhausted CD8+ T cells.